Bristol Myers Squibb has responded swiftly to a UK ruling that invalidated a patent protecting the Eliquis (apixaban) anticoagulant that it developed with Pfizer, with the originator pledging to appeal against the decision involving Sandoz and Teva at the same time as litigation continues over a separate family of apixaban formulation patents.
On 7 April, the England and Wales High Court’s Patents Court ruled that apixaban’s European Patent (UK) 1,427,415 B1...






